Eddy A A
J Am Soc Nephrol. 1994 Dec;5(6):1273-87. doi: 10.1681/ASN.V561273.
Although chronic progressive tubulointerstitial (TI) disease plays a critical role in the outcome of patients with primary glomerular lesions, the basic mechanisms that generate the TI damage remain unclear. This review focuses on recent insights into this process that originate primarily from studies of animal models of glomerular injury. The acute phase, which is often clinically silent, is characterized by tubular epithelial cell injury and interstitial inflammation. Proposed mediators of tubular injury include antibodies, lysosomal enzymes, obstruction, reactive oxygen metabolites, and complement. Damaged tubules may regenerate or undergo necrosis or apoptosis. The identification of the molecular mediators of mononuclear cell recruitment to the interstitium is of current interest because of evidence that monocytes/macrophages play a key role in progressive interstitial scarring through the release of fibrosis-promoting cytokines, particularly transforming growth factor-beta 1 (TGF-beta 1). Events linked to the initiation of interstitial inflammation include the deposition of antibodies or immune complexes along the tubular basement membranes, T cell-dependent mechanisms, glomerular factors, and factors linked to proteinuria. Several molecules likely regulate the interstitial migration of circulating monocytes, although the critical mediators are presently unknown. Candidates include chemotactic factors such as intercrines, growth factors, complement, lipid factors, osteopontin, and monocyte adhesion molecules (beta 1 integrins, beta 2 integrins, and L-selectins). The hallmark of the chronic phase of TI damage is interstitial fibrosis. Of the several candidate fibrogenic cytokines, to date, only TGF-beta 1 has been studied in any detail. TGF-beta 1 is produced by interstitial inflammatory cells and appears to trigger increased matrix production by perivascular and interstitial fibroblasts. Awaiting clarification is the role of tubular cells in vivo as a source of fibrogenic cytokines or as a site of increased matrix synthesis, activities they do perform in vitro. Preliminary studies suggest that interstitial fibrosis may also be due in part to the failure of matrix degradation by metalloproteinases and plasmin as a result of the overexpression of the enzyme inhibitors. The existence of an intrarenal matrix-degrading enzyme cascade suggests that renal fibrosis may be reversible, at least to a limited extent. In summary, during the early stage of glomerular injury, numerous cellular and molecular mediators of acute interstitial disease are activated and ultimately converge on common pathways that lead to progressive renal scarring.
尽管慢性进行性肾小管间质(TI)疾病在原发性肾小球病变患者的预后中起着关键作用,但导致TI损伤的基本机制仍不清楚。本综述主要关注近期对这一过程的见解,这些见解主要源于对肾小球损伤动物模型的研究。急性期通常在临床上没有症状,其特征为肾小管上皮细胞损伤和间质炎症。推测的肾小管损伤介质包括抗体、溶酶体酶、梗阻、活性氧代谢产物和补体。受损的肾小管可能再生,也可能发生坏死或凋亡。单核细胞募集至间质的分子介质的鉴定是当前研究的热点,因为有证据表明单核细胞/巨噬细胞通过释放促纤维化细胞因子,特别是转化生长因子-β1(TGF-β1),在进行性间质瘢痕形成中起关键作用。与间质炎症起始相关的事件包括抗体或免疫复合物沿肾小管基底膜的沉积、T细胞依赖性机制、肾小球因子以及与蛋白尿相关的因子。尽管目前关键介质尚不清楚,但有几种分子可能调节循环单核细胞的间质迁移。候选分子包括趋化因子,如白细胞介素、生长因子、补体、脂质因子、骨桥蛋白和单核细胞黏附分子(β1整合素、β2整合素和L-选择素)。TI损伤慢性期的标志是间质纤维化。在几种候选的促纤维化细胞因子中,迄今为止,只有TGF-β1得到了较为详细的研究。TGF-β1由间质炎症细胞产生,似乎可触发血管周围和成纤维细胞的基质产生增加。肾小管细胞在体内作为促纤维化细胞因子的来源或作为基质合成增加的部位所起的作用尚待阐明,而它们在体外确实发挥这些作用。初步研究表明,间质纤维化也可能部分归因于金属蛋白酶和纤溶酶因酶抑制剂的过度表达而导致的基质降解功能障碍。肾内存在基质降解酶级联反应提示肾纤维化至少在一定程度上可能是可逆的。总之,在肾小球损伤的早期阶段,急性间质疾病的众多细胞和分子介质被激活,并最终汇聚于导致进行性肾瘢痕形成的共同途径。